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AbstrAct
Introduction Comorbidities in patients with chronic 
obstructive pulmonary disease (COPD) generate a 
major burden on healthcare. Identification of cost-
effective strategies aiming at preventing and enhancing 
management of comorbid conditions in patients with 
COPD requires deeper knowledge on epidemiological 
patterns and on shared biological pathways explaining co-
occurrence of diseases.
Methods The study assesses the co-occurrence of 
several chronic conditions in patients with COPD using two 
different datasets: Catalan Healthcare Surveillance System 
(CHSS) (ES, 1.4 million registries) and Medicare (USA, 
13 million registries). Temporal order of disease diagnosis 
was analysed in the CHSS dataset.
results The results demonstrate higher prevalence of 
most of the diseases, as comorbid conditions, in elderly 
(>65) patients with COPD compared with non-COPD 
subjects, an effect observed in both CHSS and Medicare 
datasets. Analysis of temporal order of disease diagnosis 
showed that comorbid conditions in elderly patients with 
COPD tend to appear after the diagnosis of the obstructive 
disease, rather than before it.
conclusion The results provide a population health 
perspective of the comorbidity challenge in patients with 
COPD, indicating the increased risk of developing comorbid 
conditions in these patients. The research reinforces 
the need for novel approaches in the prevention and 
management of comorbidities in patients with COPD to 
effectively reduce the overall burden of the disease on 
these patients.
IntroductIon
Projections on healthcare impact of chronic 
obstructive pulmonary disease (COPD) over 
the next 15 years indicate a rapidly escalating 
health and societal burden mainly due to 
population ageing and comorbidities.1 2 It 
is well-known that highly prevalent chronic 
conditions such as cardiovascular disorders, 
type 2 diabetes mellitus—metabolic syndrome 
and/or anxiety–depression often occur as 
comorbid conditions in patients with COPD.3 
Whereas the current standards on COPD 
management4 acknowledge the adverse 
effects of comorbidities on COPD prognosis, 
they suggest that ‘presence of comorbidities 
should not alter COPD treatment, and comor-
bidities should be treated per usual stan-
dards regardless of the presence of COPD’. 
However, recent evidence prompts the need 
for novel approaches in the prevention and 
management of comorbidities in patients 
with COPD to effectively reduce the overall 
burden of the disease.5 6
Identification of such cost-effective strat-
egies aiming at preventing and enhancing 
management of comorbid conditions in 
patients with COPD requires deeper knowl-
edge on epidemiological patterns and shared 
biological pathways explaining co-occurrence 
of diseases.7 Recently, Gomez-Cabrero et al8 
reported the higher risk of developing certain 
comorbidities in patients with COPD, as 
compared with patients without COPD. The 
study used a data-driven analysis of Medicare 
registries from 13 million hospitalised patients 
over 65 years. The authors also proposed 
underlying biological mechanisms that may 
explain the identified comorbidities. Another 
direction of comorbidity research aims to 
uncover temporal disease co-occurrence 
patterns, showing great potential to explain 
Key messages
 ► Patients with COPD show higher risk for developing 
certain comorbidities than non-COPD patients, inde-
pendent of the population (ES, USA) and the specific-
ities of the healthcare system.
 ► In elderly patients, COPD diagnosis tend to precede 
the appearance of other comorbid conditions, rather 
thanbe diagnosed after them.
 ► A better knowledge on the underlying shared molec-
ular mechanisms  of comorbidities in patients with 
COPD emerges as major priority for the development 
of cost-effective strategies to prevent comorbidities. copyright.
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the dynamics of disease co-occurrence and to highlight 
characteristic disease sequences potentially caused by 
underlying mechanisms and common risk factors. As 
an example, a recent study identified COPD as a central 
disease with rapid progression to many other conditions, 
stressing the importance of its early diagnosis.9
In order to gain deeper knowledge on epidemiolog-
ical patterns explaining co-occurrence of diseases,7 the 
primary aim of the current study is to reinforce previous 
evidence on the higher risk of comorbidities in patients 
with COPD.8 To this end, we conducted a similar analysis 
to the recent work by Gomez-Cabrero et al8 on an inde-
pendent dataset retrieved from the Catalan Healthcare 
Surveillance System (CHSS) in Spain,10 which accounts 
for 1.4 million patients over 65 years with chronic condi-
tions recruited across all healthcare tiers. The research 
also explored the temporal order of disease diagnosis 
of COPD and comorbidities at a population level which 
might help to further understand the dynamics of comor-
bidity clustering often seen in patients with COPD.3 11
Methods
dataset and study population
The study is based on registry data of over 7.6 million 
inhabitants retrieved from the CHSS, including: primary 
care consultations, hospital-related events (hospital-
isations, emergency room consultations and special-
ised outpatient visits), pharmacy, mental health events, 
socio-sanitary services and other items, such as home-
based respiratory therapies, dialysis, outpatient rehabil-
itation and non-urgent healthcare transportation.12 13 
The study used a cross-sectional analysis, incorporating 
all patients over 65 years and registered in the CHSS who 
were active and alive during 2016 (n=1 433 376).
The research considered only chronic conditions of 
the patients, expressed with the Chronic Condition Indi-
cator for International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) coding 
(Agency for Healthcare Research and Quality, USA).14 
Diagnosis of COPD was based on the ICD-9 coding 
(online supplementary table S1) declared by the patient’s 
responsible physician, either a primary care professional 
or a specialist. The study did not take into account back-
ground clinical information nor forced spirometry data. 
The study identified patient with COPD (n=2 11 418) 
and their concomitant diseases, which were aggregated 
in 27 disease groups (DGs) (see online supplementary 
table S2) representing clinically significant traits.8 
DGs with <1% prevalence in the study population were 
excluded from the study.
Heterogeneities between the Medicare dataset8 and 
the current study were identified (table 1) and were 
taken into account in the analysis of the results. Briefly, 
the Medicare dataset included registries from hospital-
ised patients over 65 years, considering both acute and 
chronic conditions, from 1990 to 1993. In contrast, the 
current study considered chronic diagnosis of patients 
over 65 years during 2016, obtained from a broader 
healthcare scenario, including all hospital visits since 
2005 as well as diagnoses made in the primary care 
centres since the first visit of the patient.
statistical analysis
For each DG, period prevalence was computed as the 
proportion of existing DG cases between 1 January 
2016 and 31 December 2016 compared with the total 
population in the dataset. Age-associated prevalence 
was computed for each DG in patients with COPD and 
without COPD for 5-year age windows between ages 
65 and 90 (eg, 75 denotes the prevalence between 73 and 
77 years, both included).
Comorbidity association between COPD and DGs was 
measured using relative risk (RR) and phi correlation 
coefficient (Φ) (for detailed definition, see online supple-
mentary methods).8 15 Significance of these measures 
were assessed at the stringent threshold p<0.0001, 
associated with a Bonferroni corrected p-value<0.01. 
Healthcare system-related differences in comorbidity 
associations were compared using two-sided t-tests of RR 
measures, where p<0.0001 was considered significant.
temporal order of disease diagnosis
Diagnosis history of the patients included in the CHSS 
registries was used to study the temporal order of disease 
diagnosis (COPD ↔ disease). Date of diagnosis for a 
given DG was defined by the first diagnosis of any corre-
sponding disease in the DG. Patient DG diagnoses, made 
before and after the COPD diagnosis, were counted to 
characterise their temporal order. Cases in which COPD 
was diagnosed simultaneously with other DGs for the first 
time in the same visit were disregarded from the temporal 
analysis (see online supplementary figure S1).
Table 1 Description of the datasets and methodological considerations of the current study and the previous study of 
Gomez-Cabrero and colleagues8
Study population Study period Scope of data
Diseases 
considered
Current study 1.4 million (CHSS) 2016
+diagnosis history
Primary care, hospital 
claims, social care, others
Chronic
Gomez-Cabrero et al8 13 million (Medicare) 1990–1993 Hospital claims Chronic, acute
CHSS, Catalan Healthcare Surveillance System.
copyright.











es: first published as 10.1136/bm




Tényi Á, et al. BMJ Open Resp Res 2018;5:e000302. doi:10.1136/bmjresp-2018-000302 3
Open access
For significant comorbid conditions, the directionality 
of temporal order of disease diagnosis was tested. Preferred 
direction (the one that appears more often) was assigned 
to those COPD–DG pairs where significantly more 
patients were diagnosed with the DG before COPD or the 
other way around, using a binomial test for each direc-
tion with a probability of success equals to 0.5 and sample 
size NDG+Nsimultaneous+ NCOPD, where Nsimultaneous indicates the 
number of patients with simultaneous first diagnosis of 
COPD and the DG.9 To estimate the strength of the direc-
tional associations, the causal information fraction (CIF) 
was used, which, in contrast to RR and Φ, considers the 
order of occurrence of the disease pairs and emphasises 
possible causative effects.16 CIF is defined between a pair 
of diseases i and j, as




2N   
where  ni   and  nj   denote the prevalence of the diseases, 
 ni→j   is the number of individuals diagnosed with disease 
i followed by disease j and N is the population size. In 
the current analysis, CIF was used to compute COPD–DG 
associations.
results
comorbidity risk in patients with coPd in different healthcare 
systems
Nine DGs were discarded from the comparative analysis 
due to containing solely acute diseases (two DGs) and 
because of showing <1% prevalence (seven DGs) (online 
supplementary table S3).
The prevalence of 18 DGs included in the analysis is 
indicated in figure 1 by the size of the bars. Comparison 
of prevalence results within the CHSS dataset (red bars) 
indicates that patients with COPD (dark colour) have 
higher risk of developing most of the DGs compared with 
a general patient of the healthcare system (light colour). 
Identical prevalence patterns are observed in the Medi-
care dataset (cyan bars). These results are also consistent 
with the analysis of COPD comorbidity risk based on 
comorbidity measures (ie, RR, Φ-correlation), indicating 
significant (p<0.0001) disease association between COPD 
and all the DGs in both healthcare systems (online supple-
mentary table S3). The comparative analysis between 
the two datasets (figure 1) shows significant differences 
in the RR for several DGs that are fully explainable by 
the heterogeneities in the data sources described in the 
section Methods. For example, acute diseases, not consid-
ered in the current analysis (CHSS), accounted for more 
than 90% of Medicare cases in endocrine disorders and skin 
alterations (online supplementary table S4) leading to the 
visible differences in prevalence.
Figure 2 compares the age-associated prevalence of 
heart diseases, circulatory disorders and digestive alterations8 
between patients with COPD and without COPD in the 
two datasets. The figure indicates that in the two datasets 
the prevalence of the three DGs is consistently higher in 
patients with COPD (red lines), and that similar age-associ-
ated comorbidity patterns are observed. Interestingly, the 
prevalence of heart diseases for the two groups, COPD and 
non-COPD, is higher in the Medicare dataset than in the 
current study, representative of a Mediterranean popula-
tion with mostly non-hospitalised patients. However, prev-
alence of heart diseases increases more steeply with age in 
the CHSS dataset. Similar age-associated prevalence of 
Figure 1 Prevalence (x axis) of disease groups (DGs) 
(y axis) in the population of Medicare (light cyan) and 
Catalan Healthcare Surveillance System (CHSS) (light red), 
and in patients with chronic obstructive pulmonary disease 
(COPD) in Medicare (dark cyan) and in CHSS (dark red). 
The comparative analysis within datasets shows that the 
prevalence of most of the DGs is higher in patients with 
COPD (dark colour) than in the entire population (light 
colour). Differences in the prevalence between datasets 
are fully explainable by methodological heterogeneities, 
detailed in the main text. Healthcare system-related 
differences in comorbidity associations were compared 
using two-sided t-tests of relative risk measures (*), 
p<0.0001.
copyright.
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the remaining DGs in the CHSS dataset is displayed in 
online supplementary figure S2.
temporal order of disease diagnosis
The analysis of temporal order of disease diagnosis with 
respect to COPD is shown in figure 3A. Red bars indicate 
the patients in whom the first diagnosis of a disease from 
a given DG was done before the diagnosis of COPD. The 
number of patients in whom the corresponding DG was 
identified after the diagnosis of COPD are indicated by 
the cyan bars. It is of note, that for the majority of DGs, 
COPD was diagnosed first (G1). Interestingly, only heart 
diseases (G2) were more often diagnosed before COPD 
than after COPD. A  third group of DGs (G3) showed no 
preferred direction. Figure 3B translates these interac-
tions to a network representation, with directional edges 
based on the grouping and directional strengths of the 
association (ie, CIF measure).
dIscussIon
The current research confirms in the CHSS dataset that 
patients with COPD are in higher risk of developing 
certain comorbidities than in patients without COPD, 
along with the results reported in Gomez-Cabrero et al .8 
Despite marked methodological heterogeneities, similar 
age-related prevalence patterns were also observed 
between the current study and the Medicare dataset in 
elderly patients, as displayed in figure 2. These results 
provide a population health perspective of the comor-
bidity challenge in patients with COPD. It is of note that 
they are in line with a recent independent report carried 
out using a similar population-based analysis.17
It is known that clinical prevalence of certain comor-
bidities is higher in patients with COPD than in those 
without COPD.18 19 In this study, we show that this effect 
is also observable using registry data, independent of 
the population (ES, USA) and the specificities of the 
healthcare system (figure 1). This relation also persists 
if studying both acute and chronic (Medicare, USA) or 
only chronic diseases (CHSS, ES), suggesting the validity 
of disease interactions on the functional trait level repre-
sented by the DGs. Interestingly, age-related patterns of 
elevated comorbidity risk are similarly observable in the 
different healthcare systems reinforcing that this effect is 
persistent in the elderly population (>65 years).
The results also showed that comorbid conditions in 
elderly patients with COPD tend to appear after the diag-
nosis of the obstructive disease, which seems to be in line 
with other studies on disease trajectories.9 20 Different 
reports17 21 have suggested age-dependent comorbidity 
patterns in patients with COPD, which indicate an inter-
esting direction for future analysis of temporal order of 
disease diagnoses. Furthermore, the results showing the 
distinguished role of cardiovascular health in COPD are 
also in line with earlier studies on comorbidity clustering21 
and with its consistent relation to systemic effects of the 
Figure 2 Comparison of the age-associated prevalence (y axis) in the Catalan Healthcare Surveillance System (CHSS) and 
Medicare datasets of selected disease groups in patients with chronic obstructive pulmonary disease (COPD) (red) and non-
COPD (blue) individuals over windows of 5 years (x axis). This figure shows that patients with COPD in both datasets showed 
a higher risk for heart disease, circulatory disorders and digestive alterations. copyright.
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disease.22 23 This indicate potential synergies between the 
management of pulmonary and cardiovascular health and 
the promotion of physical activity from early stages of the 
disease with the potential to modulate prognosis in these 
patients.
The increased risk of developing comorbid conditions 
in patients with COPD, as well deleterious interactions 
among concurrent diseases,24 25 indicates the need for 
refining current strategies aiming at reducing the burden 
of COPD on healthcare systems. In this context, prevention 
and appropriate treatment of comorbidities arise as central 
goals in the management of patients with COPD. These 
considerations are especially relevant in light of reports 
indicating that the majority of hospital admissions (and 
increased patients costs) are associated with comorbidities 
instead of the pulmonary events.6
Considering the high predictive potential of comorbidity 
groupers on these events,6 further evaluation of other 
modalities of disease interactions, such as temporal order of 
appearance,9 26 concomitant clinical characteristics,21 life-
style and genetic risk,27 constitute as interesting next step 
towards high accuracy health risk prediction, as proposed 
in Dueñas-Espín et al.10 Furthermore, a better knowledge 
of the underlying molecular mechanisms that modulate 
susceptibility for developing comorbidities in patients with 
COPD also emerges as major priority. It constitutes an 
initial step toward elaboration of cost-efficient strategies to 
prevent comorbid conditions.28
However, a large-scale combined approach is indispens-
able in order to define efficient strategies coping with 
comorbidity clustering in patients with COPD. It involves 
meaningful integration of registry data with other infor-
mation sources reflecting a broader health status, such 
as electronic health records, environmental and occupa-
tional exposures and genetic risks. Furthermore, the evolu-
tion of population-based analyses towards personalised 
approaches, such as identifying personal disease progres-
sion9 26 or their transcriptional patterns29 and comparing 
it with similar patients profiles,30–32 is needed to address 
disease heterogeneity often seen in COPD and to progress 
towards personalised health risk assessment and service 
selection.6 10
Finally, it is acknowledged that risk of developing comor-
bidities can be modulated by confounding risk factors 
Figure 3 (A) Temporal order of pairwise diagnoses in patients with chronic obstructive pulmonary disease (COPD). Red 
bars show the number of patients whose first diagnosis of a disease from the corresponding disease group (DG) happened 
before COPD, whereas cyan bars show the cases when such diagnoses were done after COPD. DGs are grouped into 
preferred directions: (1) G1, DG diagnosis after COPD, (2) G2, disease diagnosis before COPD and (3) G3, no significant 
directionality. (B) Elderly comorbidity network. Network nodes represent COPD and the different DGs. DGs are coloured by 
their directionality grouping: cyan for G1, red for G2 and grey for G3. The size of the nodes is proportional to the number of 
cases affected by both COPD and the DG, colour and thickness of edges are proportional to the strength of the directional 
association based on the causal information fraction measure. It is of note that simultaneous diagnoses were excluded from 
the analysis or accounted for when computing binomial directionality. This mainly influenced the data shown on respiratory 
diseases (>45% of COPD diagnoses were made simultaneously, online supplementary figure S1).
copyright.
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not included in the current analysis, such as degree of 
airflow limitation and smoking history. It is important to 
note, however, that risk factors alone cannot explain the 
observed effects,17 33 which reinforces the need for a large-
scale, combined approaches incorporating patient infor-
mation at population and patient-specific level.
It is acknowledged that registry information alone reflects 
underdiagnosis of COPD and the lack of forced spirometry 
data constitutes a significant limitation for accurate diag-
nosis of COPD. These barriers also indicate the need for 
speeding-up efforts to facilitate integration between clin-
ical and registry data.
conclusIon
The current research confirms that patients with COPD 
are in higher risk of developing certain comorbidities than 
patients without COPD. The study results, as well as ongoing 
research on time-related analyses of disease trajectories,7 9 
strengthen the need for further investigations on under-
lying mechanisms of non-pulmonary phenomena observed 
in patients with COPD with focus on altered regulation of 
biological pathways likely shared by different comorbid 
conditions. Furthermore, the study suggests the need for 
exploring novel modalities for health risk assessment and 
patient management aiming at consolidating cost-effec-
tive strategies to prevent comorbidities.6 10 In this context, 
current standard of care recommendations4 should neces-
sarily evolve from the current organ-centred orientation to 
a systems approach.
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